HOME >> MEDICINE >> NEWS
GroPep starts Phase 1 infertility trial

GroPep's program - to develop a treatment for a condition that potentially causes 50% of all miscarriages - reached a major milestone today with commencement of recruitment of healthy women volunteers into a Phase 1 trial of its infertility drug, PV903.

The drug is targeted to treat recurrent miscarriages caused by an abnormal immune response to the foetus a condition for which there is no current treatment.

The market for a drug to treat this condition is estimated to be up to US$750 million annually.

Listed biopharmaceutical company GroPep Limited (ASX:GRO) announced today that it will commence a Phase 1 trial of its infertility drug PV903. The trial, which will be conducted under the Therapeutic Goods Administration Clinical Trial Notification scheme, was approved by the Royal Adelaide Hospital Research Ethics Committee.

Recruitment will begin immediately to allow medical screening and enrolment of the first cohort of subjects in mid-February 2006. The results of the trial should be known in late 2006, depending on recruitment rate.

The trial, conducted at the CMAX Adelaide-based facilities, involves healthy female volunteers each receiving a single administration of PV903 gel (or placebo) as they are enrolled sequentially into three groups with the PV903 dose escalating between groups. A total of 36 volunteers will complete the trial. The objectives of the trial are to evaluate the safety and tolerability of vaginally administered PV903 gel, and to determine whether PV903 has effects on vaginal immune cells in a manner consistent with its proposed role in treating immunebased infertility.

Over 50% of miscarriages have no apparent explanation and some scientists believe that women who suffer from repeated miscarriage have an immune system that attacks the embryo as "foreign". PV903 is a recombinant version of a protein that is naturally found in semen and thought to be re
'"/>

Contact: Mr Tony Mitchell
61-283-547-700
Research Australia
9-Jan-2006


Page: 1 2

Related medicine news :

1. GroPep awarded key patent for infertility treatment in Europe
2. GroPep completes final milestone of the path malaria vaccine initiative
3. GroPep to pursue promising asthma drug following preclinical study results
4. GroPep licenses technology to TGR BioSciences
5. GroPep news: Key psoriasis patent granted in Japan and new asthma patent filed for GroPep drug
6. Coffee jump-starts short-term memory
7. Epidemiology in Europe: the problem starts in childhood
8. GSK announces launch of largest ever Phase III trial in lung cancer treatment
9. Phase II study shows combination improves survival of metastatic melanoma patients
10. MacroChem completes patient enrollment for Phase II trial of EcoNail for treatment of onychomycosis
11. Drug combination proves effective against myeloma in Phase I trial

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/27/2020)... Calif. (PRWEB) , ... March 27, 2020 , ... ... focused on addressing unmet needs in the field of urology, today announced that ... as a UroLift® Center of Excellence. The designation recognizes that Dr. Wadhwa has ...
(Date:3/22/2020)... (PRWEB) , ... March 21, 2020 , ... ... communication, announces easy-to-implement solutions that hospitals, medical organizations, and health centers can use ... adapts to the coronavirus pandemic, many medical professionals are working around the clock ...
(Date:3/20/2020)... ... March 20, 2020 , ... CommunityMed Urgent Care ... clinics. The virtual waiting room lets patients present online, complete registration paperwork (including ... queue, wait for their turn, and get signaled that their clean exam room is ...
(Date:3/19/2020)... ... March 19, 2020 , ... For weeks, SignatureCare Emergency ... cases. , Earlier this week, it announced that while we are still short of ... virus will not wait for our preparedness measures to be complete. , The Houston, ...
(Date:3/19/2020)... ... March 19, 2020 , ... “We wanted to solve ... said Dr. Viral Patel, Founder of Radish Health. “A reliable at home testing kit ... peace of mind they need in the comfort of their own home, while maintaining ...
Breaking Medicine News(10 mins):
(Date:3/20/2020)... ... March 20, 2020 , ... Suntuity ... companies with its US headquarters in New Jersey, recently launched a new initiative ... affected and present in the local communities across New Jersey, Maryland and Florida. ...
(Date:3/20/2020)... , ... March 21, 2020 , ... On March 19, ... Trailer Triage at Adventist Health Simi Valley. The ramp and platforms helped access the ... to be an essential service as we install ramps that provide access to medical ...
(Date:3/16/2020)... ... ... In the wake of the COVID-19 pandemic, Curogram , the leading ... to help the containment of the global disease with its virtual clinic, two-way text ... system. , “Our goal is to minimize exposure and maximize providers’ resources during ...
Breaking Medicine Technology:
Cached News: